A Prospective obsERvational Study to asSEss the Effectiveness of Intravitreal Aflibercept Injection in roUtine Clinical Practice in Treatment Naive patientS With Wet Age-related Macular Degeneration in Greece
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 02 Feb 2018
At a glance
- Drugs Aflibercept (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- Acronyms PERSEUS-GR
- Sponsors Bayer
- 29 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 30 Nov 2017 Planned End Date changed from 15 Mar 2019 to 30 Sep 2019.
- 30 Nov 2017 Planned primary completion date changed from 15 Mar 2019 to 30 Sep 2019.